IL17A and psoriasis vulgaris: Recently, multiple randomized control trials have been published about Secukinumab, a human anti-IL-17A IgG1κ monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.9,18 Their initial results are promising, however cost will remain a major factor for their widespread use, an important consideration in Third World countries like Pakistan.